About: Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
Creator	Mueller, Thomas Austria, Bundschuh, Christian Clodi, Martin Dieplinger, Benjamin Egger, Margot Gabriel, Christian Linz, Linz, Ordensklinikum Schwestern, Barmherzige Wiesinger, Kurt
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Besides SARS-CoV-2 RT-PCR testing, serological testing is emerging as additional option in COVID-19 diagnostics. Aim of this study was to evaluate novel immunoassays for detection of SARS-CoV-2 antibodies in human plasma. METHODS: Using EDI(TM) Novel Coronavirus COVID-19 Enzyme Linked Immunosorbent Assays (ELISAs), we measured SARS-CoV-2 IgM and IgG antibodies in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: The positivity rates in the COVID-19 patients were 5.9% for IgM and 2.9% for IgG ≤5 days after symptom onset; Between day 5 and day 10 the positivity rates were 37.1% for IgM and 37.1% for IgG and rose to 76.4% for IgM and 82.4% for IgG after >10-15 days. After 15-22 days the “true” positivity rates were 94.4% for IgM and 100% for IgG. The “false” positivity rates were 0.5% for IgM and 1.0% for IgG in the healthy blood donors, 1.6% for IgM and 1.2% for IgG in ICU patients. CONCLUSIONS: This study shows high “true” vs. low “false” positivity rates for the EDI(TM) SARS-CoV-2 IgM and IgG ELISAs.
has issue date	2020-06-08(xsd:dateTime)
bibo:doi	10.1016/j.cca.2020.05.047
bibo:pmid	32526218
has license	no-cc
sha1sum (hex)	9e4e65b99df777bb06c38f640401cadfd9663975
schema:url	https://doi.org/10.1016/j.cca.2020.05.047
resource representing a document's title	Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma
has PubMed Central identifier	PMC7278646
has PubMed identifier	32526218
schema:publication	Clin Chim Acta
resource representing a document's body	covid:9e4e65b99df777bb06c38f640401cadfd9663975#body_text
is schema:about of	named entity 'antibody' named entity 'SARS-CoV-2' named entity 'plasma' named entity 'enzyme' named entity 'EVALUATE' named entity '1945' named entity 'DIAGNOSTICS' named entity 'IGG' named entity 'DETECTION' named entity 'option' named entity 'Evaluation' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity 'IgG antibodies' named entity 'human plasma' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'IgM' named entity 'plasma' named entity 'Clinical and Laboratory Standards Institute' named entity 'SARS-CoV-2' named entity 'serologic' named entity 'seroconversion' named entity 'plasma' named entity 'ICU' named entity 'IgM' named entity 'clinical evaluation' named entity 'serological' named entity 'antibodies' named entity 'antibody tests' named entity 'lower respiratory' named entity 'EP5' named entity 'SARS-CoV-2' named entity 'IgG antibodies' named entity 'IgG' named entity 'seroconversion' named entity 'nucleocapsid protein' named entity 'ELISAs' named entity 'IgG antibodies' named entity 'infection' named entity 'SPSS Inc.' named entity 'RT-PCR' named entity 'COVID' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'blood samples' named entity 'IgM' named entity 'plasma' named entity 'IgM' named entity 'IgG' named entity 'ELISAs' named entity 'ICU' named entity 'IgG' named entity 'blood donors' named entity 'seroconversion' named entity 'blood samples' named entity 'microwell plate' named entity 'IgM' named entity 'IgG' named entity 'RT-PCR' named entity 'IgG antibody' named entity 'IgG antibodies' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'IgM' named entity 'EDI' named entity 'COVID' named entity 'COVID' named entity 'plasma' named entity 'symptom' named entity 'RT-PCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software